infectious diseases
Lipoglycopeptides
Dosing Considerations for Lipoglycopeptides
Dalbavancindoses should be reduced in patients with creatinine clearance < 30 mL/minute; clinicians should use 1125 mg for single-dose regimens or 750 mg once followed by 375 mg 1 week later. No dosage adjustment is recommended for patients who are regularly receiving hemodialysis. Oritavancindoes not appear to require renal dose adjustment, but adequate studies to support a recommendation for patients with renal failure have not been done. Telavancindosing is based on creatinine clearance: Creatinine clearance > 50 mL/minute: 10 mg/kg IV every 24 hours Creatinine clearance 30 to 50 mL/minute: 7.5 mg/kg every 24 hours Creatinine clearance 10 to < 30 mL/minute: 10 mg/kg every 48 hours Creatinine clearance < 10 mL/minute: Data limited, no recommendations available 